BioXcel Therapeutics, Inc. (BTAI) Key Metrics
BTAI valuation today
Trailing 12 months · as of September 13, 2026- Market cap
- $2.3M
- Enterprise value
- $93.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.1
- Price / book
- 27.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.19
BTAI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBTAI returns How much profit the business earns on the capital it uses.
Return on assets−61.5 pts
−167.9%
2025 · hover or tap a bar for each year
20162025
Asset turnover−61.9%
0.02
2025 · hover or tap a bar for each year
20162025
BTAI financial health Debt, liquidity and how easily interest is covered.
Net debt+$8.2M
$81.2M
2025 · hover or tap a bar for each year
20162025
Current ratio−50.7%
0.83
2025 · hover or tap a bar for each year
20162025
Interest coverage
-3.0
2025 · hover or tap a bar for each year
20162025
Debt / assets−9.1%
2.44
2025 · hover or tap a bar for each year
20162025
BTAI efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+87 days
103 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+1,332 days
1,559 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+31,629 days
34,153 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−30,210 days
-32,491 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
BTAI valuation history
Fiscal year-endToday10-year median
BTAI returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BTAI debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BTAI cash returned to shareholders
DividendsBuybacksFree cash flow
BTAI price vs earnings per share
Share price at year-endEPS (right axis)
BTAI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $19.5M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $100.8M | — | — | — | — | — | — | — | — | — |
| Price / sales | 30.4 | — | — | — | — | — | — | — | — | — |
| EV / sales | 157.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −357.8% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −295.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.60 | $5.98 | $47.20 | $343.68 | $325.28 | $739.20 | $233.76 | $61.76 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.05 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$5.73 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$4.72 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$4.72 | — | — | — | — | — | — | — | — | — |
| Cash per share | $2.33 | — | — | — | — | — | — | — | — | — |
| Book value per share | −$7.82 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$7.82 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $8.98 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 12.2M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | −111.1% | −49.8% | −70.2% | −98.3% | −101.7% | — | — |
| Return on assets (ROA) | −167.9% | −106.4% | −128.1% | −74.4% | −46.4% | −64.0% | −80.9% | −85.8% | −666.5% | — |
| Return on tangible assets | −155.6% | −155.5% | −242.9% | −80.5% | −44.5% | −37.3% | −88.9% | −44.2% | −335.0% | — |
| Financial health | ||||||||||
| Total debt | $109.7M | $102.9M | $101.4M | $94.2M | $1.4M | $1.6M | $1.0M | — | $371,000 | — |
| Cash & short-term investments | $28.4M | $29.9M | $65.2M | $193.7M | $233.0M | $213.1M | $32.4M | $42.6M | $887,000 | — |
| Net debt | $81.2M | $73.1M | $36.2M | −$99.6M | −$231.6M | −$211.5M | −$31.4M | −$42.6M | −$516,000 | — |
| Debt / equity | — | — | — | 1.23 | 0.01 | 0.01 | 0.04 | — | — | — |
| Debt / assets | 2.44 | 2.69 | 1.38 | 0.46 | 0.01 | 0.01 | 0.03 | — | 0.27 | — |
| Current ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 | 18.33 | 4.03 | 9.26 | 0.38 | 0.01 |
| Quick ratio | 0.82 | 1.65 | 2.57 | 6.11 | 14.21 | 18.33 | 4.03 | 9.26 | 0.38 | 0.01 |
| Interest coverage | -3.0 | -4.4 | -12.9 | -19.4 | — | — | — | — | — | — |
| Working capital | −$9.2M | $15.2M | $44.9M | $170.0M | $220.1M | $205.2M | $25.6M | $38.5M | −$1.4M | −$329,000 |
| Invested capital | −$14.2M | −$20.0M | −$20.3M | −$22.8M | −$9.9M | −$4.8M | −$4.5M | −$3.7M | −$1.5M | −$324,000 |
| Tangible asset value | −$95.5M | −$93.1M | −$56.5M | $76.8M | $221.7M | $206.7M | $26.9M | $38.9M | −$982,000 | −$324,000 |
| Net current asset value | −$95.7M | −$94.0M | −$58.1M | $73.8M | $219.0M | $203.8M | $24.6M | $38.5M | −$1.4M | −$329,000 |
| Graham net-net per share | −$9.13 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | $27,000 | $0 | $0 | $9.0M | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 0.0% | 1.4% | 37.1% | — | 1,300,411.5% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.06 | 0.43 | 1.50 | 1.68 | 5.58 | 20.00 | 340.00 | 0.00 |
| Stock-based compensation / revenue | 431.0% | 271.7% | 1,348.8% | 4,623.2% | — | 60,127,572.0% | — | — | — | — |
| R&D / revenue | 4,712.0% | 1,343.1% | 6,110.6% | 24,330.4% | — | 238,662,551.4% | — | — | — | — |
| SG&A / revenue | 3,192.2% | 1,522.2% | 6,044.4% | 18,336.3% | — | 101,427,983.5% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 103.5 | 16.3 | 42.2 | 120.7 | — | — | — | — | — | — |
| Days of inventory on hand | 1,559.0 | 227.4 | 575.9 | 18,113.1 | — | — | — | — | — | — |
| Days payables outstanding | 34,153.1 | 2,524.5 | 3,459.1 | 136,017.2 | 5,319.5 | 8,670.7 | 7,670.8 | 21,985.9 | 131,947.5 | — |
| Cash conversion cycle (days) | -32,490.6 | -2,280.9 | -2,841.0 | -117,783.4 | — | — | — | — | — | — |
| Receivables turnover | 3.53 | 22.44 | 8.65 | 3.02 | — | — | — | 0.00 | — | — |
| Payables turnover | 0.01 | 0.14 | 0.11 | 0.00 | 0.07 | 0.04 | 0.05 | 0.02 | 0.00 | 0.00 |
| Inventory turnover | 0.23 | 1.61 | 0.63 | 0.02 | — | — | — | — | — | — |
| Asset turnover | 0.02 | 0.04 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $182,000 | $101,000 | $159,500 | $124,000 | $0 | — | — | $115,000 | — | — |
| Average payables | $15.3M | $14.8M | $11.9M | $7.5M | $4.3M | $4.5M | $3.3M | $1.0M | $361,500 | $279,000 |
| Average inventory | $700,500 | $1.3M | $2.0M | $992,500 | $0 | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BTAI's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BTAI valuation and financial ratios
It ended the year with $109.7 million of debt and $28.4 million in cash and short-term investments, net debt of $81.2 million.
See the BTAI income statement, the BTAI chart for price history, or the BTAI stock overview for the latest quote and news.
BTAI key metrics FAQ
How much debt does BioXcel Therapeutics have?
BioXcel Therapeutics had total debt of $109.7 million at the end of fiscal 2025.
What is BioXcel Therapeutics's free cash flow yield?
BioXcel Therapeutics generated -$57.6 million of free cash flow in fiscal 2025, a free cash flow yield of −295.0% on its market value at year-end ($19.5 million).
What is BioXcel Therapeutics's current ratio?
BioXcel Therapeutics's current ratio was 0.83 at the end of fiscal 2025: current assets were 0.83 times current liabilities.